Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Focusing on social processes contributing to marginalization can help clinicians and policy makers mitigate food insecurity risk through improved patient-centered care.
AMA J Ethics. 2018;20(10):E941-947. doi:
10.1001/amajethics.2018.941.
Produce prescription programs can expand patient's food choices and provide financial incentives to change consumption behaviors. If these programs are not linked to established government assistance programs, however, growers could be at risks for bearing the cost.
AMA J Ethics. 2018;20(10):E960-973. doi:
10.1001/amajethics.2018.960
Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.